Showing results (381-390 of 513) with videos related to

Sort By:
Pageof 52
Bone Marrow Transplantation|January 17, 2017
Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplantsB E Shaw, N P Mayor, R M Szydlo, et al.
Mycoses|August 27, 2016
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplantCarlos Solano, Monica Slavin, Alissa J Shaul, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 14, 2020
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular TherapyAbraham S Kanate, Navneet S Majhail, Bipin N Savani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 11, 2015
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow TransplantationNavneet S Majhail, Stephanie H Farnia, Paul A Carpenter, et al.
Trials|October 16, 2015
Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trialClaire M Rice, David I Marks, Yoav Ben-Shlomo, et al.
The Lancet. Oncology|June 19, 2010
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysisMary Eapen, Vanderson Rocha, Guillermo Sanz, et al.
Blood|October 18, 2002
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantationDavid I Marks, Richard Lush, Jamie Cavenagh, et al.
Leukemia|March 17, 2015
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignanciesR F Olsson, B R Logan, S Chaudhury, et al.
The Lancet. Haematology|July 9, 2017
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, et al.
Haematologica|November 18, 2021
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trialsThomas Creasey, Emilio Barretta, Sarra L Ryan, et al.
Pageof 52